公开(公告)号：US20240358741A1

公开(公告)日：2024-10-31

申请号：US18687950

申请日：2022-08-31

Applicant: POLYRIZON LTD.

Inventor： Tomer IZRAELI ,  Tidhar TURGEMAN ,  Eyal RON

IPC: A61K31/738 ,  A61K9/00 ,  A61K9/70 ,  A61K47/36 ,  A61P31/14 ,  A61P31/16 ,  A61P37/08

CPC classification number: A61K31/738 ,  A61K9/0043 ,  A61K9/7015 ,  A61K47/36 ,  A61P31/14 ,  A61P31/16 ,  A61P37/08

Abstract: The invention generally concerns with mucosal protective agents, and specifically, to the agents acting on the nasal mucosa. To that end, the invention provides a series of mucoadhesive polymeric compositions and methods, which can be used per se as blocking agents against a wide range of microbial pathogens and allergens, or as smart drug delivery systems of actives through the oral and/or nasal mucosa.

公开(公告)号：US12128136B2

公开(公告)日：2024-10-29

申请号：US16499618

申请日：2018-04-02

Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

Inventor： Edward E. Morrisey ,  Jason A. Burdick ,  Leo Wang

IPC: A61K9/06 ,  A61K31/7105 ,  A61K47/36 ,  A61P9/04

CPC classification number: A61K9/06 ,  A61K31/7105 ,  A61K47/36 ,  A61P9/04

Abstract: The present disclosure provides microRNA-based therapies using a hydrogel delivery system that provides regenerative approach to myocardial infarction by targeting cardiomyocytes. The hydrogel provides for local and sustained cardiac delivery of microRNAs, such miR-302 mimics that can be used to promote cardiomyocyte proliferation. Also provided are compositions suitable for local and sustained release and methods for intramyocardial gel delivery of a miRNA oligonucleotide.

公开(公告)号：US20240350593A1

公开(公告)日：2024-10-24

申请号：US18621336

申请日：2024-03-29

Applicant: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) ,  SORBONNE UNIVERSITE ,  UNIVERSITÉ PARIS CITÉ ,  ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS

Inventor： Francine BEHAR-COHEN ,  Raphael COHEN ,  Rinath LEVY-BOUKRIS ,  Min ZHAO

IPC: A61K38/38 ,  A61K38/01 ,  A61K47/36 ,  A61P27/02 ,  A61K31/573

CPC classification number: A61K38/38 ,  A61K38/014 ,  A61K47/36 ,  A61P27/02 ,  A61K31/573

Abstract: This invention relates to the treatment of macular edema. Macular edema is the main cause of vision loss during diabetic macular edema, wet AMD (Age Related Macular Degeneration), retinal vein occlusion and chronic intraocular inflammation. Currently, beyond photocoagulation by laser irradiation, two types of drugs are used, protein molecules that neutralize VEGF family members and glucocorticoids, with different mechanisms of action, but targeting one single symptom: macular edema. The inventors have now found that macular edema may be treated by increasing the oncotic pressure of the vitreous. According to the inventors' understanding, causing an increase in the oncotic pressure of the vitreous induces a liquid flow from the interstitial water accumulated in the retina tissue to the vitreous compartment, so as to reduce or stop macular edema. Increasing the oncotic pressure of the vitreous is preferably performed by intravitreal injection of an oncotic pressure-increasing macromolecule, which macromolecule may be selected in a group comprising protein or non-protein macromolecules, such as albumin, gelatin, alpha2 macroglobulin, fibrinogen, haptoglobin multimers, beta lipoproteins and antibodies, as well as dextran and hydroxyethyl starch.

公开(公告)号：US20240350434A1

公开(公告)日：2024-10-24

申请号：US18760811

申请日：2024-07-01

Applicant: iX Biopharma Limited ,  iX Biopharma Ltd

Inventor： Yip Hang Eddy LEE ,  Chin Beng Stephen LIM

IPC: A61K31/135 ,  A61K9/00 ,  A61K47/36

CPC classification number: A61K31/135 ,  A61K9/006 ,  A61K47/36

Abstract: The invention concerns methods of using a ketamine dosage form in treating depression and, in particular, major depressive disorder and treatment-resistant depression, comprising administering to a patient in need thereof, a fast dissolving freeze-dried wafer solid dosage form with a matrix for rapid release and absorption of ketamine in the oral cavity of the said patient.

公开(公告)号：US20240342454A1

公开(公告)日：2024-10-17

申请号：US18579663

申请日：2022-07-11

Applicant: LTS LOHMANN THERAPIE-SYSTEME AG

Inventor： Markus Winterberg

IPC: A61M37/00 ,  A61K9/00 ,  A61K31/155 ,  A61K47/36

CPC classification number: A61M37/0015 ,  A61K9/0021 ,  A61K31/155 ,  A61K47/36 ,  A61M2037/0023 ,  A61M2037/0053

Abstract: The present invention relates to a microneedle array for use in the intradermal application of active substances, the array comprising a plurality of microneedles on a support which are formed of a formulation that contains a biodegradable polymer, an active substance and an antiseptic.

公开(公告)号：US20240335422A1

公开(公告)日：2024-10-10

申请号：US18297862

申请日：2023-04-10

Applicant: Xygenyx Inc.

Inventor： Alexy Goldstein

IPC: A61K31/401 ,  A61K9/00 ,  A61K9/06 ,  A61K31/198 ,  A61K33/34 ,  A61K36/886 ,  A61K47/36

CPC classification number: A61K31/401 ,  A61K9/0014 ,  A61K9/06 ,  A61K31/198 ,  A61K33/34 ,  A61K36/886 ,  A61K47/36

Abstract: A composition comprising an aqueous gel with therapeutically effective amounts of arginine; proline; glycine; aloe vera gel; and a penetration enhancer. The penetration enhancer may comprise a form of hyaluronic acid, and the addition of a therapeutically effective amount of copper (II) acetate or undeclenoyl phenylalanine may also be used.

公开(公告)号：US12109314B2

公开(公告)日：2024-10-08

申请号：US17049095

申请日：2019-04-24

Applicant: FUJI CAPSULE CO., LTD.

Inventor： Yuki Obatake ,  Yosuke Kondo ,  Koji Masuda ,  Kazuhiko Watanabe ,  Yoshihiko Watanabe

IPC: A61K9/48 ,  A61K47/36

CPC classification number: A61K9/4816 ,  A61K47/36

Abstract: A soft capsule film composition, comprising: (A) a native gellan gum; (B) one or more hydrophilic polysaccharides; (C) a starch or modified starch; (D) a plasticizer; and (E) water, wherein a gelling agent other than the native gellan gum and the one or more hydrophilic polysaccharides is not an essential component. The soft capsule film composition shortens drying time at room temperature, suppresses the stickiness of the surface of a film sheet, imparts film sheet strength which can withstand continuous production in factory manufacturing with a rotary die filling machine or the like, and enables the manufacture of a good soft capsule with high adhesiveness. For this reason, the soft capsule produced using the soft capsule film composition can be utilized for various uses such as drugs, quasi drugs, cosmetics, and foods.

公开(公告)号：US12109307B2

公开(公告)日：2024-10-08

申请号：US17261411

申请日：2019-07-19

Applicant: The Hong Kong University Of Science and Technology

Inventor： Ying Chau ,  Chi Ming Laurence Lau ,  Yu Yu

IPC: A61K47/20 ,  A61K9/00 ,  A61K9/06 ,  A61K47/36 ,  C08L5/02

CPC classification number: A61K9/06 ,  A61K9/0019 ,  A61K47/20 ,  A61K47/36 ,  C08L5/02

Abstract: The present disclosure provides compositions and methods for controlled release of macromolecules (such as proteins and polypeptides). The present disclosure also provides method for preparing and using the same.

公开(公告)号：US20240325543A1

公开(公告)日：2024-10-03

申请号：US18615167

申请日：2024-03-25

Applicant: Johnson & Johnson Consumer Inc.

Inventor： Charleine Apangha Ngantsan ,  Vincent Chen ,  Julia Coskey ,  Michael Costante

IPC: A61K47/26 ,  A61K9/10 ,  A61K31/09 ,  A61K31/137 ,  A61K31/138 ,  A61K31/167 ,  A61K31/192 ,  A61K31/445 ,  A61K31/451 ,  A61K31/485 ,  A61K31/495 ,  A61K41/00 ,  A61K47/10 ,  A61K47/12 ,  A61K47/36 ,  A61K47/46

CPC classification number: A61K47/26 ,  A61K9/10 ,  A61K31/09 ,  A61K31/137 ,  A61K31/138 ,  A61K31/167 ,  A61K31/192 ,  A61K31/445 ,  A61K31/451 ,  A61K31/485 ,  A61K31/495 ,  A61K41/0004 ,  A61K47/10 ,  A61K47/12 ,  A61K47/36 ,  A61K47/46

Abstract: Therapeutic liquid compositions useful in the treatment of various conditions comprising a natural bulk sweetener that has a low fructose content.

公开(公告)号：US20240324656A1

公开(公告)日：2024-10-03

申请号：US18743359

申请日：2024-06-14

Applicant: Japan Tobacco Inc.

Inventor： Takeshi HAMAMOTO ,  Shoko ENDO

IPC: A24B15/40 ,  A24B13/00 ,  A24B15/16 ,  A61K31/465 ,  A61K47/36

CPC classification number: A24B15/403 ,  A24B13/00 ,  A24B15/16 ,  A61K31/465 ,  A61K47/36

Abstract: Provided is a composition for an oral product, the composition comprising an alginic acid compound having a weight-average molecular weight of 10,000-900,000 and selected from the group consisting of alginic acid, salts thereof, esters thereof, and combinations of the foregoing.